---
title: "Intermittent Parasite Clearance (IPC) in Schools: Impact on Malaria, Anaemia and Cognition"
nct_id: NCT01454752
overall_status: COMPLETED
phase: NA
sponsor: London School of Hygiene and Tropical Medicine
study_type: INTERVENTIONAL
primary_condition: Malaria
countries: Senegal
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01454752.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01454752"
ct_last_update_post_date: 2012-04-19
last_seen_at: "2026-05-12T06:42:50.684Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Intermittent Parasite Clearance (IPC) in Schools: Impact on Malaria, Anaemia and Cognition

**Official Title:** Intermittent Parasite Clearance (IPC) in Schools: a Randomised Double-blind Placebo-controlled Trial of the Impact of IPC on Malaria, Anaemia and Cognition Amongst School Children in Kedougou, Senegal

**NCT ID:** [NCT01454752](https://clinicaltrials.gov/study/NCT01454752)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 860
- **Lead Sponsor:** London School of Hygiene and Tropical Medicine
- **Collaborators:** Division Controle Medicale Scolaire, Ministry of Education, Senegal, Ministry of Health, Senegal, Institut National d'Etude et d'Action pour le Developpement de l'Education, Senegal, Cheikh Anta Diop University, Senegal, Institut de Recherche pour le Developpement, Senegal, Harvard University
- **Conditions:** Malaria, Anaemia
- **Start Date:** 2011-11
- **Completion Date:** 2012-02
- **CT.gov Last Update:** 2012-04-19

## Brief Summary

Although the risk of malaria is greatest in early childhood, significant numbers of schoolchildren remain at risk from malaria infection, clinical illness and death. By the time they reach school, many children have already acquired some clinical immunity and the ability to limit parasite growth, and thus most infections are asymptomatic and will go undetected and untreated. Asymptomatic parasitaemia contributes to anaemia, reducing concentration and learning in the classroom, and interventions aiming to reduce asymptomatic parasite carriage may bring education, as well as health, benefits.

Intermittent parasite clearance (IPC) delivered through schools is a simple intervention, which can be readily integrated into broader school health programmes, and may usefully supplement the community-distribution of insecticide-treated nets (ITNs) in countries with a policy of universal coverage of nets.

This study seeks to establish whether intermittent parasite clearance undertaken once a year at the end of the malaria transmission season can reduce malaria parasite carriage and anaemia amongst school-going children already using insecticide-treated nets, and its consequent impact on school attendance and performance, in order to assess its suitability for inclusion as a standard intervention in school health programmes in areas of seasonal malaria transmission.

## Eligibility

- **Minimum age:** 7 Years
- **Maximum age:** 14 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* enrolled in participating elementary schooled
* provision of parental consent

Exclusion Criteria:

* lack of consent
* chronic conditions which limit regular school attendance
* clinical malaria on the day of scheduled treatment (as defined as febrile, with a positive result in a rapid diagnostic test for malaria).
```

## Arms

- **Intermittent parasite clearance** (ACTIVE_COMPARATOR) — Children sleeping under a long-lasting insecticidal net (LLIN) receive an additional intermittent preventive treatment for clearance of asymptomatic malaria infection given once a year at the end of the malaria transmission season
- **Control** (PLACEBO_COMPARATOR) — Children sleeping under a long-lasting insecticidal net (LLIN) receive placebo

## Interventions

- **Intermittent parasite clearance** (DRUG) — Sulphadoxine-pyrimethamine (500/25mg) according to age, given on day 1; Amodiaquine (200mg) according to age, given daily for 3 days
- **Placebo** (OTHER) — Placebo tablets, similar in appearance and taste to active treatment, given daily over 3 days

## Primary Outcomes

- **Prevalence of malaria parasitaemia** _(time frame: 8 weeks after treatment (February 2012))_
- **Prevalence of anaemia (Haemoglobin<11 g/dL)** _(time frame: 8 weeks after treatment (February 2012))_

## Secondary Outcomes

- **Cognitive performance in tests of sustained attention** _(time frame: 8 weeks after treatment (February 2012))_

## Locations (1)

- Institut de Recherche pour le Developpement, Dakar, Senegal

## Recent Field Changes (last 30 days)

- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.institut de recherche pour le developpement|dakar||senegal` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01454752.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01454752*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*